The Top 5 Biosimilars Articles for the Week of August 26

August 30, 2019

The Center for Biosimilars® recaps the top stories for the week of August 26, 2019.

Transcript

Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of August 26, 2019.

Number 5: A new report shows that employers could see substantial savings from biosimilars, but those savings won’t come without a concerted effort to encourage biosimilar use.

Number 4: The International Coalition of Medicines Regulatory Authorities has released a statement of confidence in biosimilars.

Number 3: According to the Centers for Disease Control and Prevention, women are more likely than men not to take their diabetes medications as prescribed in an effort to save on high drug costs.

Number 2: A recent cost simulation found that, when taking on-body device failure into account, biosimilar filgrastim has better cost efficiency than Neulasta.

Number 1: A new treatment guideline for axial spondyloarthritis strongly recommends that stable patients not be required to switch to a biosimilar.

Finally, last week, our e-newsletter asked whether you think that oncology biosimilars are on a better road to US uptake than biosimilars that treat inflammatory diseases.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Content:

News | Business

x